Jose Baselga
何塞·巴塞尔加
MD, PhD
Physician-in-Chief (Emeritus)首席医师（荣誉）
👥Biography 个人简介
Jose Baselga made foundational contributions to HER2-targeted therapy development, including pivotal work on pertuzumab and lapatinib. His research on HER2 biology and resistance mechanisms shaped the modern treatment landscape for HER2+ breast cancer. He contributed to seminal clinical trials establishing dual HER2 blockade as standard of care.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Pertuzumab Development
Led early clinical development of pertuzumab, contributing to the CLEOPATRA trial demonstrating dual HER2 blockade superiority in metastatic HER2+ breast cancer.
PI3K Pathway in Breast Cancer
Made major contributions to understanding PI3K/AKT pathway role in breast cancer and HER2 inhibitor resistance.
Representative Works 代表性著作
Phase II trial of pertuzumab in patients with HER2-positive, trastuzumab-refractory metastatic breast cancer
Annals of Oncology (2010)
Established pertuzumab activity in trastuzumab-refractory HER2+ disease.
Lapatinib with capecitabine for HER2-positive advanced breast cancer
NEJM (2006)
EGF100151 trial leading to lapatinib approval.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 何塞·巴塞尔加 的研究动态
Follow Jose Baselga's research updates
留下邮箱，当我们发布与 Jose Baselga（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment